bioRxiv · 10.1101/2025.08.13.670104
ALK1-BMPRII agonism by clustering bispecific antibodies treats hereditary hemorrhagic telangiectasia
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is characterized by arteriovenous malformations (AVMs) and severe bleeding caused by loss-of-function mutations in the ALK1 receptor pathway. We developed clustering agonist bispecific antibodies (BsAbs) targeting ALK1 and its activating partner, the Ser/Thr receptor kinase BMPRII. These BsAbs induced ALK1-BMPRII proximity association, stimulated the downstream Smad1/5/8 signaling cascade, and treated HHT pathologies in various mouse models. BsAb treatment reduced AVM burden by up to 95% in HHT mice, preventing anemia, cardiomegaly, and premature death. The BsAbs also enhanced Smad1/5/8 signaling in endothelial cells derived from HHT patients with ALK1 mutations and prevented retinal AVMs in a newly developed knock-in mouse carrying an HHT-causing ALK1 mutation. These findings establish ALK1-BMPRII agonism as a promising therapeutic strategy for HHT.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Qutaina, S., Zhao, H., Wang, Z., Sullivan, A., Geddie, M., Kaur, R., Tian, H., Yue, H., Wang, X., Guo, S., Bruni, M., Christen, E., Campagne, F., Arthur, H. M., Andre, P., Marambaud, P.. 2025-08-14. ALK1-BMPRII agonism by clustering bispecific antibodies treats hereditary hemorrhagic telangiectasia. https://doi.org/10.1101/2025.08.13.670104
Cite the original work for its findings. Save a collection to share your selection of sources.